Status:
UNKNOWN
Hypertension Registry of "Hypertension Prevention and Control Initiative in China"
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Hypertension is the leading preventable risk factor of cardiovascular disease globally and in China. Unparalleled to remarkable increase of hypertension burden in China, blood pressure(BP) control is ...
Detailed Description
Objective: The study aims to investigate the clinical features, treatment, blood pressure control and outcomes of hypertension patients managed in the "Hypertension Prevention and Control Initiative i...
Eligibility Criteria
Inclusion
- Age ≥ 18 years.
- Residing in the local administrative area for at least 6 months.
- Hypertension：defined as systolic blood pressure (SBP) ≥140 mmHg and/or /diastolic blood pressure (DBP) ≥90 mmHg and/or use of antihypertensive medication within two weeks.
- Informed consent.
Exclusion
- patients under pregnancy or lactation.
- patients with severe liver or renal diseases.
- patients with history of malignant tumor.
- patients with mental illness that impair their consent.
Key Trial Info
Start Date :
October 8 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2024
Estimated Enrollment :
200000 Patients enrolled
Trial Details
Trial ID
NCT04289701
Start Date
October 8 2019
End Date
December 30 2024
Last Update
February 28 2020
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affliated Hospital of Anhui Medical University
Hefei, Anhui, China, 230022
2
Chinese Academy of Medical Sciences，Fuwai Hospital
Beijing, Beijing Municipality, China, 100037
3
Beijing Shunyi District Hospital
Beijing, Beijing Municipality, China, 101300
4
First affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150001